Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase.

Jathal MK, Steele TM, Siddiqui S, Mooso BA, D'Abronzo LS, Drake CM, Whang YE, Ghosh PM.

Br J Cancer. 2019 Jul;121(3):237-248. doi: 10.1038/s41416-019-0496-4. Epub 2019 Jun 18.

PMID:
31209328
2.

Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.

Clin Genitourin Cancer. 2019 Aug;17(4):275-282.e1. doi: 10.1016/j.clgc.2019.04.013. Epub 2019 Apr 18.

PMID:
31171481
3.

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.

Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, Collichio FA.

J Immunother Cancer. 2019 Jan 8;7(1):4. doi: 10.1186/s40425-018-0475-y.

4.

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.

Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, Kardos J, Drier A, Basch E, Godley PA, Dunn MW, Kim WY, Milowsky MI.

Br J Cancer. 2018 Oct;119(7):801-807. doi: 10.1038/s41416-018-0229-0. Epub 2018 Oct 8.

PMID:
30293995
5.

ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS, Wang GG.

Mol Cell. 2018 Oct 18;72(2):341-354.e6. doi: 10.1016/j.molcel.2018.08.029. Epub 2018 Sep 27.

PMID:
30270106
6.

Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints.

Stump SE, Whang YE, Crona DJ.

Invest New Drugs. 2018 Dec;36(6):1143-1146. doi: 10.1007/s10637-018-0629-2. Epub 2018 Jun 28.

PMID:
29956055
7.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20. Erratum in: J Clin Oncol. 2018 May 20;36(15):1541.

8.

Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.

Crona DJ, Whang YE.

Cancers (Basel). 2017 Jun 12;9(6). pii: E67. doi: 10.3390/cancers9060067. Review.

9.

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.

Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, Perou CM, Soper JT, Whang YE, Yeh JJ, Martin G, Soper SA.

NPJ Precis Oncol. 2017;1. pii: 24. doi: 10.1038/s41698-017-0028-8. Epub 2017 Jul 25.

10.
11.

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.

Crona DJ, Milowsky MI, Whang YE.

Clin Pharmacol Ther. 2015 Dec;98(6):582-9. doi: 10.1002/cpt.256. Epub 2015 Oct 1. Review.

12.

Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps.

Whang YE, Hayes DN.

JAMA Oncol. 2015 Jul;1(4):541. doi: 10.1001/jamaoncol.2015.0936. No abstract available.

PMID:
26181266
13.

Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.

Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI.

Urol Oncol. 2015 Sep;33(9):386.e1-6. doi: 10.1016/j.urolonc.2015.05.028. Epub 2015 Jun 27.

14.

Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding.

Karaca M, Liu Y, Zhang Z, De Silva D, Parker JS, Earp HS, Whang YE.

PLoS One. 2015 May 7;10(5):e0126270. doi: 10.1371/journal.pone.0126270. eCollection 2015.

15.

Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer.

Crona DJ, Whang YE.

Invest New Drugs. 2015 Jun;33(3):751-4. doi: 10.1007/s10637-014-0193-3. Epub 2014 Dec 3.

16.

Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs).

Hupert ML, Jackson JM, Wang H, Witek MA, Kamande J, Milowsky MI, Whang YE, Soper SA.

Microsyst Technol. 2014 Oct 1;20(10-11):1815-1825.

17.

Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.

Chism DD, De Silva D, Whang YE.

Expert Rev Anticancer Ther. 2014 Nov;14(11):1369-78. doi: 10.1586/14737140.2014.928594. Epub 2014 Jun 13. Review.

18.

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):909-16. doi: 10.1007/s00280-013-2250-6. Epub 2013 Aug 7.

PMID:
23921574
19.

Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLD.

Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Rathmell WK, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI.

Urol Oncol. 2014 Jan;32(1):32.e1-9. doi: 10.1016/j.urolonc.2012.11.019. Epub 2013 Feb 19.

20.

Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.

Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, Rathmell WK, Godley PA, Whang YE.

BJU Int. 2012 Dec;110(11 Pt B):E721-6. doi: 10.1111/j.1464-410X.2012.11536.x. Epub 2012 Sep 27.

21.

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.

Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M.

Invest New Drugs. 2013 Jun;31(3):669-76. doi: 10.1007/s10637-012-9857-z. Epub 2012 Jul 25.

PMID:
22828917
22.

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.

Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ.

Urol Oncol. 2013 Jan;31(1):82-6. doi: 10.1016/j.urolonc.2010.09.018. Epub 2011 Mar 10.

PMID:
21396844
23.
24.

Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

Bae-Jump VL, Zhou C, Boggess JF, Whang YE, Barroilhet L, Gehrig PA.

Gynecol Oncol. 2010 Dec;119(3):579-85. doi: 10.1016/j.ygyno.2010.08.025. Epub 2010 Sep 21.

25.

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; Cancer and Leukemia Group B.

Cancer. 2011 Feb 1;117(3):526-33. doi: 10.1002/cncr.25421. Epub 2010 Sep 22.

26.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

27.

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK.

J Clin Oncol. 2010 Mar 20;28(9):1502-7. doi: 10.1200/JCO.2009.24.7759. Epub 2010 Feb 16.

28.

Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.

Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA.

Urol Oncol. 2011 Nov-Dec;29(6):608-13. doi: 10.1016/j.urolonc.2009.09.012. Epub 2009 Dec 21.

PMID:
20022268
29.

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.

Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43. Epub 2007 May 9.

30.

The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells.

Hsiang CH, Tunoda T, Whang YE, Tyson DR, Ornstein DK.

Prostate. 2006 Sep 15;66(13):1413-24.

PMID:
16741918
31.

Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability.

Majumder S, Liu Y, Ford OH 3rd, Mohler JL, Whang YE.

Prostate. 2006 Sep 1;66(12):1292-301.

PMID:
16705743
32.

Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines.

Boggess JF, Zhou C, Bae-Jump VL, Gehrig PA, Whang YE.

Gynecol Oncol. 2006 Nov;103(2):417-24. Epub 2006 May 11.

PMID:
16690106
33.

The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.

Zhou C, Bae-Jump VL, Whang YE, Gehrig PA, Boggess JF.

Gynecol Oncol. 2006 May;101(2):305-10. Epub 2005 Dec 27.

PMID:
16380156
34.
35.

Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.

Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF.

Gynecol Oncol. 2006 Mar;100(3):487-94. Epub 2005 Oct 24.

PMID:
16249016
36.

p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression.

Wu W, Silbajoris RA, Whang YE, Graves LM, Bromberg PA, Samet JM.

Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L883-9. Epub 2005 Jun 24.

37.

Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS, Whang YE.

Cancer Res. 2005 Apr 15;65(8):3404-9.

38.

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS 3rd.

Clin Cancer Res. 2005 Mar 1;11(5):1704-12.

39.

Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.

Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD.

Vitam Horm. 2004;67:409-26. Review.

PMID:
15110188
40.

Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.

Zhou C, Gehrig PA, Whang YE, Boggess JF.

Mol Cancer Ther. 2003 Aug;2(8):789-95.

41.

The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity.

Nan B, Snabboon T, Unni E, X-J Yuan, Whang YE, Marcelli M.

J Mol Endocrinol. 2003 Aug;31(1):169-83.

PMID:
12914534
42.

Renal cell carcinoma.

Whang YE, Godley PA.

Curr Opin Oncol. 2003 May;15(3):213-6. Review.

PMID:
12778014
43.

Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells.

Wu W, Wang X, Zhang W, Reed W, Samet JM, Whang YE, Ghio AJ.

J Biol Chem. 2003 Jul 25;278(30):28258-63. Epub 2003 May 12.

44.

Human epidermal receptor-2 expression in prostate cancer.

Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL.

Clin Cancer Res. 2003 Mar;9(3):1087-97.

45.

Hypertriglyceridemia and pancreatitis associated with estramustine phosphate.

Olson EL, Whang YE.

Am J Clin Oncol. 2002 Aug;25(4):342-3.

PMID:
12151961
47.

PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit.

Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin AS Jr, Whang YE.

J Biol Chem. 2002 Mar 29;277(13):11116-25. Epub 2002 Jan 17.

48.

Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.

Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, Whang YE, Stanbridge EJ.

Mol Cell Biol. 2001 Sep;21(17):5846-56.

49.

c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.

Whang YE, Tran C, Henderson C, Syljuasen RG, Rozengurt N, McBride WH, Sawyers CL.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5486-91.

50.

Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2.

Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, Whang YE.

Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4233-8.

Supplemental Content

Loading ...
Support Center